ALLMedicine™ Acid Phosphatase Center

Aug 30th, 2021 - DNA damage-inducible transcript 3 (DDIT3), a member of the CCAAT/enhancer-binding protein (C/EBP) family, is involved in cellular apoptosis and differentiation. DDIT3 participates in the regulation of adipogenesis and osteogenesis in vitro and in ...

Aug 29th, 2021 - Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytoki...

Aug 14th, 2021 - Matrix protein is a kind of secretory protein that regulates the biomineralization of the bivalve shell. In this study, a water-soluble matrix protein (WSMP) from Pacific oysters (Crassostrea gigs) shell was isolated, and its structure was analyze...

Aug 11th, 2021 - Parathyroid hormone (PTH) acts on bone to indirectly increase the number and activity of osteoclasts. Thus, PTH has a stimulatory effect on bone resorption and upregulates bone turnover. However, the responsiveness of bone to PTH varies widely amo...

Aug 6th, 2021 - Cholesteatoma-related bone destruction is the cause of many complications due to chronic otitis media. This study aimed to evaluate osteoclastic activity in cholesteatoma-related bone destruction using tartrate-resistant acid phosphatase 5b, an en...

Dec 9th, 2020 - NEW YORK (Reuters Health) - Monthly intravenous ibandronate is associated with increases in bone mineral density (BMD) and bone microstructure benefits in women with osteoporosis after teriparatide treatment, according to new findings. Once teripa...

Aug 21st, 2020 - NEW YORK (Reuters Health) - Postmenopausal women with osteoporosis who are treatment-naive have the greatest early response to romosozumab (ROMO), according to new research. Improvements in lumbar spine (LS) and femoral neck (FN) bone-mineral dens...

Apr 3rd, 2019 - Treatment of Metastatic CRPC (M1 Disease) As with M0 CRPC, ADT should be continued in patients with mCRPC to maintain castration levels of testosterone while initiating additional treatments. Several drugs for the treatment of mCRPC have been appr.

Aug 4th, 2018 - Raoul S. Concepcion, MD, FACS As we are all keenly aware, there is not a day that passes when our email inbox doesn’t include news of a genetic discovery that contributes to the ever-expanding body of knowledge in the prostate cancer world. The pr...

Dec 9th, 2017 - NATIONAL HARBOR, MD. – Combining programmed death (PD)-1 blockade with tumor-targeted T-cell activation by a novel DNA vaccine safely enhanced antitumor immune responses in metastatic castration-resistant prostate cancer (mCRPC) patients in a rand.